JP2006525288A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525288A5
JP2006525288A5 JP2006505607A JP2006505607A JP2006525288A5 JP 2006525288 A5 JP2006525288 A5 JP 2006525288A5 JP 2006505607 A JP2006505607 A JP 2006505607A JP 2006505607 A JP2006505607 A JP 2006505607A JP 2006525288 A5 JP2006525288 A5 JP 2006525288A5
Authority
JP
Japan
Prior art keywords
sequence
type
amino acid
information
length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006505607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525288A (ja
Filing date
Publication date
Priority claimed from ES200301054A external-priority patent/ES2246105B1/es
Application filed filed Critical
Publication of JP2006525288A publication Critical patent/JP2006525288A/ja
Publication of JP2006525288A5 publication Critical patent/JP2006525288A5/ja
Pending legal-status Critical Current

Links

JP2006505607A 2003-05-08 2004-05-03 アルツハイマー病治療方法 Pending JP2006525288A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
PCT/ES2004/000194 WO2004098631A1 (es) 2003-05-08 2004-05-03 Método de tratamiento de la enfermedad de alzheimer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011191515A Division JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Division JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法

Publications (2)

Publication Number Publication Date
JP2006525288A JP2006525288A (ja) 2006-11-09
JP2006525288A5 true JP2006525288A5 (https=) 2007-02-08

Family

ID=32982086

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006505607A Pending JP2006525288A (ja) 2003-05-08 2004-05-03 アルツハイマー病治療方法
JP2011191515A Pending JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Withdrawn JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法
JP2016003772A Withdrawn JP2016065100A (ja) 2003-05-08 2016-01-12 アルツハイマー病治療方法
JP2018088643A Pending JP2018119011A (ja) 2003-05-08 2018-05-02 アルツハイマー病治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2011191515A Pending JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Withdrawn JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法
JP2016003772A Withdrawn JP2016065100A (ja) 2003-05-08 2016-01-12 アルツハイマー病治療方法
JP2018088643A Pending JP2018119011A (ja) 2003-05-08 2018-05-02 アルツハイマー病治療方法

Country Status (19)

Country Link
US (6) US20090162362A1 (https=)
EP (5) EP2082747A3 (https=)
JP (5) JP2006525288A (https=)
CN (2) CN101264326A (https=)
AT (1) ATE435024T1 (https=)
AU (2) AU2004237373A1 (https=)
BR (1) BRPI0410684A (https=)
CA (1) CA2524571C (https=)
CY (1) CY1109454T1 (https=)
DE (1) DE602004021797D1 (https=)
DK (3) DK2356996T5 (https=)
ES (6) ES2246178B1 (https=)
IL (8) IL171651A (https=)
MX (1) MXPA05010914A (https=)
PL (3) PL2075007T3 (https=)
PT (3) PT2075007E (https=)
RU (2) RU2385161C2 (https=)
SI (1) SI1623719T1 (https=)
WO (1) WO2004098631A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
EP1959996A2 (en) * 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
AU2008311367B2 (en) * 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
BR112012014060B8 (pt) 2009-12-11 2021-07-27 Araclon Biotech Sl método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
DE69126304T2 (de) 1990-04-27 1997-09-04 Mcmichael, John, Delanson, N.Y. Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
ATE239797T1 (de) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
AU759945B2 (en) * 1998-08-20 2003-05-01 Regents Of The University Of California, The Methods for labeling beta-amyloid plaques and neurofibrillary tangles
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20070128191A1 (en) * 2001-12-26 2007-06-07 Universidad De Zaragoza Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
US20040146512A1 (en) * 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Similar Documents

Publication Publication Date Title
JP2006525288A5 (https=)
JP2012530145A5 (https=)
DK1531791T3 (da) Forebyggelse og begrænsning af iskæmi
JP2014510518A5 (https=)
NZ579566A (en) Modified fgf-21 polypeptides and their uses
RU2014131605A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
JP2023551122A5 (https=)
JP2004535461A5 (https=)
EP2386566A3 (en) Chi-conotoxin peptides (II)
EA201100459A1 (ru) Композиции, включающие интерлейкин-1 и пептиды
EP4676509A2 (en) Rippled antiparallel cross-beta dimers and related materials, compositions and methods
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
RU2007119376A (ru) Тимус - специфический белок
TAKAGI et al. Amino acid sequence of troponin C obtained from ascidian (Halocynthia roretzi) body wall muscle
ES2834125T3 (es) Síntesis de compuestos cíclicos peptidomiméticos de giro beta
Bitar The primary structure of the ribosomal protein L29 from Escherichia coli
JP2021506815A5 (https=)
Ilisz et al. High-performance liquid chromatography of biologically important, small epimeric peptides and their L, D-amino acid content
WO2001009174A3 (en) Plant defensin variants
JP2005501544A5 (https=)
WO2004064780A3 (en) Peptide-based angiogenesis inhibitors and methods of use thereof
JP2003522184A5 (https=)
JP2009503092A5 (https=)
JP2002534996A5 (https=)
EP1572725A4 (en) NEW CHI-CONOTOXINPEPTIDE (-I)